3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
2768
Carcinoma, Non-Small-Cell Lung
2267
Prostatic Neoplasms
1427
Colorectal Neoplasms
1295
Neoplasms
1260
Multiple Myeloma
1086
Lung Neoplasms
1050
Neoplasm Metastasis
995
Leukemia, Myeloid, Acute
985
Lymphoma
900
Melanoma
864
Pancreatic Neoplasms
819
Ovarian Neoplasms
805
Carcinoma, Hepatocellular
782
Stomach Neoplasms
754
Recurrence
753
Leukemia
733
Lymphoma, Non-Hodgkin
685
Leukemia, Lymphocytic, Chronic, B-Cell
665
Squamous Cell Carcinoma of Head and Neck
618
Lymphoma, Large B-Cell, Diffuse
617
Precursor Cell Lymphoblastic Leukemia-Lymphoma
605
Head and Neck Neoplasms
599
Brain Neoplasms
593
Carcinoma, Renal Cell
587
Glioblastoma
573
Rectal Neoplasms
565
Sarcoma
523
Myelodysplastic Syndromes
522
Lymphoma, Follicular
516
Interventions
tucatinib
1
pralsetinib
1
pertuzumab
1
ipatasertib
1
inavolisib
1
entrectinib
1
atezolizumab
1
alectinib
1
Trastuzumab
1
Tiragolumab
1
Paclitaxel
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Interventional
×
Advanced Unresectable or Metastatic Solid Malignancy
×
Clear all
NCT04632992
2025-01-08
MyTACTIC
Genentech, Inc.
Phase 2
Completed
252 enrolled
27 charts